- Home
- ABAT vs IMAB Comparison
ABAT vs IMAB Comparison
Compare ABAT & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABAT
- IMAB
- Stock Information
- Founded
- ABAT 2011
- IMAB 2014
- Country
- ABAT United States
- IMAB United States
- Employees
- ABAT N/A
- IMAB N/A
- Industry
- ABAT Metal Mining
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ABAT Basic Materials
- IMAB Health Care
- Exchange
- ABAT Nasdaq
- IMAB Nasdaq
- Market Cap
- ABAT 71.7M
- IMAB 83.8M
- IPO Year
- ABAT N/A
- IMAB 2020
- Fundamental
- Price
- ABAT $2.00
- IMAB $1.07
- Analyst Decision
- ABAT
- IMAB Strong Buy
- Analyst Count
- ABAT 0
- IMAB 3
- Target Price
- ABAT N/A
- IMAB $8.00
- AVG Volume (30 Days)
- ABAT 14.0M
- IMAB 682.1K
- Earning Date
- ABAT 02-16-2025
- IMAB 03-13-2025
- Dividend Yield
- ABAT N/A
- IMAB N/A
- EPS Growth
- ABAT N/A
- IMAB N/A
- EPS
- ABAT N/A
- IMAB N/A
- Revenue
- ABAT $545,460.00
- IMAB $3,313,984.00
- Revenue This Year
- ABAT $31,748.62
- IMAB N/A
- Revenue Next Year
- ABAT N/A
- IMAB N/A
- P/E Ratio
- ABAT N/A
- IMAB N/A
- Revenue Growth
- ABAT N/A
- IMAB N/A
- 52 Week Low
- ABAT $0.73
- IMAB $0.84
- 52 Week High
- ABAT $4.11
- IMAB $2.08
- Technical
- Relative Strength Index (RSI)
- ABAT 53.28
- IMAB 55.17
- Support Level
- ABAT $1.72
- IMAB $1.00
- Resistance Level
- ABAT $2.25
- IMAB $1.20
- Average True Range (ATR)
- ABAT 0.50
- IMAB 0.12
- MACD
- ABAT -0.09
- IMAB 0.02
- Stochastic Oscillator
- ABAT 11.72
- IMAB 40.97
About ABAT American Battery Technology Company
American Battery Technology Co is engaged in lithium-ion battery recycling, battery metals and material extraction, and resource production. It is a battery metals company producing low-cost battery metals with a commitment to closed-loop, clean energy technologies.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).